ScreenerHero
LONNLonza Group AG
SWX · CH · Healthcare · Diagnostics & Research · lonza.com
591.80CHF+1.02%Mkt Cap: 47.21B $P/E: 38.28

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DAP
Danaher Corporation
$142.58BUSDP/E 38.5
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILU
Illumina, Inc.
$30.40BUSDP/E 40.4
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.65BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMérieux S.A.
$9.55BUSDP/E 19.1
QIA
Qiagen N.V.
$8.69BUSDP/E 22.8

Key Statistics

Company
Market Cap47.21B $
Enterprise Value50.89B $
Revenue (TTM)7.84B $
Gross Profit2.64B $
Net Income (TTM)-313.86M $
Revenue/Share112.22 USD
Last Price591.80 CHF
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20.1K
CountryCH
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)38.28
P/E (Forward)26.53
PEG1.26
EV/EBITDA18.66
EV/Revenue6.49
P/S5.93
P/B5.01
EPS (TTM)15.47
EPS (Forward)21.98
52W Range
454.6098% of range594.00
52W High594.00 CHF
52W Low454.60 CHF
Profitability
Gross Margin35.35%
Oper. Margin23.41%
EBITDA Margin34.78%
Profit Margin-4.21%
ROE-3.48%
ROA-1.54%
Growth
Revenue Growth11.20%
Earnings Growth39.20%
Cash Flow & Leverage
Operating CF1.32B $
CapEx (TTM)1.57B $
FCF Margin-22.81%
FCF Yield-3.79%
Net Debt4.20B $
Net Debt/EBITDA1.54
Balance Sheet
Debt/Equity0.57
Current Ratio1.66
Quick Ratio0.59
Book Value/Sh116.37 CHF
Cash/Share6.980 CHF
Dividends
Fwd Div Rate5.000 CHF
Trail. Div Rate5.000 CHF
Div. Yield0.86%
5Y Avg Yield0.68%
Payout Ratio32.28%
Ex-Div DateMay 12, 2026
Pay DateMay 15, 2025
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)681.13 CHF
Upside (mean)+15.1%
Target Range550.00 CHF – 835.00 CHF
CHF550.00+15.1% to meanCHF835.00
# Analysts23
Ownership
Shares Out.69.84M
Float69.74M
Insiders0.09%
Institutions61.71%
Technical
SMA 50552.34 (+7.1%)
SMA 200526.24 (+12.5%)
Beta0.84
S&P 52W Chg18.16%
Avg Vol (30d)136.10K
Avg Vol (10d)99.09K
Technical Indicators
RSI (14)62.8
MACD6.3968
MACD Signal5.9761
MACD Hist.+0.4208
BB Upper589.07 CHF
BB Middle564.24 CHF
BB Lower539.41 CHF
BB Width8.80%
ATR (14)12.11 CHF
Vol Ratio (20d)0.89x